These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33635094)

  • 1. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
    Rice SJ; Belani CP
    PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
    Yan X; Li G
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer.
    Gao Y; Zhang H; Li Y; Wang D; Ma Y; Chen Q
    Clin Chim Acta; 2018 Sep; 484():272-277. PubMed ID: 29860033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer.
    Wang D; Guo D; Shi F; Zhu Y; Li A; Kong L; Teng F; Yu J
    Future Oncol; 2019 Oct; 15(29):3367-3379. PubMed ID: 31424272
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.
    Guo W; Cai S; Zhang F; Shao F; Zhang G; Zhou Y; Zhao L; Tan F; Gao S; He J
    Thorac Cancer; 2019 Apr; 10(4):761-768. PubMed ID: 30734516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 17. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
    Ma C; Yu R; Li J; Guo J; Xu J; Wang X; Liu P
    J Surg Oncol; 2022 Mar; 125(4):754-765. PubMed ID: 34811745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy.
    Topkan E; Kucuk A; Ozturk D; Ozkan EE; Besen AA; Pehlivan B; Selek U
    Can Respir J; 2024; 2024():2803044. PubMed ID: 38975012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Change of Systemic Immune-Inflammation Index Independently Predicts Survival of Colorectal Cancer Patients after Curative Resection.
    Chen Q; Wu H; Guo X; Gu K; Wang W; Chen X; Ji S; Yang H; Zhu J
    Mediators Inflamm; 2020; 2020():4105809. PubMed ID: 33293896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.